ReviewCurrent opinion in genetics & development2008
NF-kappaB and cancer-identifying targets and mechanisms.
Review in Current opinion in genetics & development, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 337 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
337 citing papers in PubMed, 3 syntheses or guidelines pooled it, 631 citations in OpenAlex.
- Leptin signaling in breast cancer and its crosstalk with peroxisome proliferator-activated receptors α and γ.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Pooled it
- Genetic Association betweenDisease markers · 2019Pooled it
- Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).Alimentary pharmacology & therapeutics · 2026Trial
- Nitric oxide-driven Warburg reprogramming at the NOS2-COX2 axis: An integrative engine of cancer hallmarks.Redox biology · 2026Review
- KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB-CD44-Akt signaling axis.Medical oncology (Northwood, London, England) · 2026Article
- The alternative NF-κB RelB subunit is a novel critical sensor of lipid metabolism to promote tumor development.Cell death & disease · 2026Article
- Paeonol-Loaded PLGA Nanoparticles Attenuate DMH-Induced Colorectal Carcinogenesis-Associated Oxidative Stress, Inflammation, and Cellular Dysregulation via Modulation of NRF2/HO-1 Signaling in Rats.International journal of molecular sciences · 2026Article
- Synbiotics as a Microbiome-Based Strategy in Colorectal Cancer.Nutrients · 2026Review
- Proteome dynamics during establishment of California grunion (Leuresthes tenuis) cell lines.BMC biology · 2026Article
- NF-κB (p65, p50), IL-18, and IL-10 as Therapeutic Targets in Prostate Cancer and BPH: Molecular Insights into Inflammation-Driven Pathogenesis.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Integrative Computational and Transcriptional Analysis of NF-κB and HIF-1α Modulation Following Doxorubicin Treatment in Triple-Negative Breast Cancer Cells.Journal of experimental pharmacology · 2026Article
- Parasitic Infections and Carcinogenesis: Molecular Mechanisms, Immune Modulation, and Emerging Therapeutic Strategies.Oncology research · 2026Review
- Structure Meets Function: Dissecting Fucoxanthin's Bioactive Architecture.Marine drugs · 2025Review
- NF-κB in inflammation and cancer.Cellular & molecular immunology · 2025Review
- Unraveling the Role of Metabolic Endotoxemia in Accelerating Breast Tumor Progression.Biomedicines · 2025Article
- SDC4 identified as an oncogenic target gene of NF-κB in TNFα-Induced tumor cells.Scientific reports · 2025Article
- NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.Inflammopharmacology · 2025Review
- Reassessing the Role of Tissue Factor Pathway Inhibitor 2 in Neoplastic and Non-Neoplastic Lesions.Cancers · 2025Review
- Role of long non-coding RNAs and natural products in prostate cancer: insights into key signaling pathways.Functional & integrative genomics · 2025Review
277 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
A connection between inflammation and carcinogenesis has long been known, but the precise mechanisms are just beginning to be understood. NF-kappaB proteins, transcription factors which integrate stress signals and orchestrate immune responses, have also recently been linked to carcinogenesis. Hallmarks of cancer development include self-sufficiency in growth signals, insensitivity to growth-inhibitors, evasion of apoptosis, limitless replicative potential, tissue invasion and metastasis, and sustained angiogenesis. NF-kappaB signaling has been implicated in each of these hallmarks, and recent experimental studies have illuminated the mechanistic pathways by which NF-kappaB signaling contributes to these aspects of carcinogenesis. This review will focus on recent experimental data supporting the hypothesis that inflammation promotes carcinogenesis, and that NF-kappaB signaling is at the heart of such inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.